SG11201700774UA - Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor - Google Patents
Biomarkers for predicting response of dlbcl to treatment with a btk inhibitorInfo
- Publication number
- SG11201700774UA SG11201700774UA SG11201700774UA SG11201700774UA SG11201700774UA SG 11201700774U A SG11201700774U A SG 11201700774UA SG 11201700774U A SG11201700774U A SG 11201700774UA SG 11201700774U A SG11201700774U A SG 11201700774UA SG 11201700774U A SG11201700774U A SG 11201700774UA
- Authority
- SG
- Singapore
- Prior art keywords
- dlbcl
- biomarkers
- treatment
- btk inhibitor
- predicting response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462032430P | 2014-08-01 | 2014-08-01 | |
US201562119668P | 2015-02-23 | 2015-02-23 | |
US201562127484P | 2015-03-03 | 2015-03-03 | |
PCT/US2015/043300 WO2016019341A1 (en) | 2014-08-01 | 2015-07-31 | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201700774UA true SG11201700774UA (en) | 2017-02-27 |
Family
ID=55179406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201700774UA SG11201700774UA (en) | 2014-08-01 | 2015-07-31 | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
Country Status (13)
Country | Link |
---|---|
US (1) | US20160032404A1 (en) |
EP (1) | EP3185870A4 (en) |
JP (1) | JP2017523188A (en) |
KR (1) | KR20170042614A (en) |
CN (1) | CN106714804A (en) |
AU (1) | AU2015296010A1 (en) |
BR (1) | BR112017001677A2 (en) |
CA (1) | CA2955744A1 (en) |
IL (1) | IL250221A0 (en) |
MX (1) | MX2017001302A (en) |
RU (1) | RU2017106794A (en) |
SG (1) | SG11201700774UA (en) |
WO (1) | WO2016019341A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2350075B1 (en) | 2008-09-22 | 2014-03-05 | Array Biopharma, Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
PT2350071E (en) | 2008-10-22 | 2014-04-11 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
BR122019024201B1 (en) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | MACROCYCLIC COMPOUND AS TRK KINASE INHIBITORS, ITS USE, AND PHARMACEUTICAL COMPOSITION |
EP2575818A4 (en) | 2010-06-03 | 2013-11-06 | Pharmacyclics Inc | The use of inhibitors of bruton's tyrosine kinase (btk) |
JP6575950B2 (en) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Mutations with resistance to Bruton tyrosine kinase (Btk) inhibitors |
WO2016071770A2 (en) * | 2014-11-05 | 2016-05-12 | Janssen Pharmaceutica Nv | Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same |
NZ731909A (en) | 2014-11-16 | 2023-11-24 | Array Biopharma Inc | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
CA3003153A1 (en) | 2015-10-26 | 2017-05-04 | Loxo Oncology, Inc. | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
CR20180501A (en) | 2016-04-04 | 2019-04-05 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
PT3458456T (en) | 2016-05-18 | 2020-12-07 | Array Biopharma Inc | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-y l)-3-hydroxypyrrolidine-1-carboxamide |
JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
US11085039B2 (en) | 2016-12-12 | 2021-08-10 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
JP7356351B2 (en) * | 2016-12-12 | 2023-10-04 | エクセラ・バイオサイエンシーズ・インコーポレイテッド | Methods and systems for screening using microcapillary arrays |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
KR20200014418A (en) | 2017-06-08 | 2020-02-10 | 엔리벡스 테라퓨틱스 리미티드 | Therapeutic Apoptosis Cells for Cancer Therapy |
CZ2017787A3 (en) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Pharmaceutical compositions containing ibrutinib |
MA52874A (en) * | 2018-06-15 | 2021-04-21 | Janssen Pharmaceutica Nv | FORMULATIONS / COMPOSITIONS INCLUDING IBRUTINIB |
GB2577909B (en) * | 2018-10-10 | 2020-11-18 | Symetrica Ltd | Gamma-ray spectrum classification |
KR20210097160A (en) * | 2018-11-30 | 2021-08-06 | 얀센 바이오테크 인코포레이티드 | Methods of Treatment of Follicular Lymphoma |
WO2021087044A1 (en) * | 2019-10-30 | 2021-05-06 | Celgene Corporation | Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma |
JP2024506855A (en) * | 2021-02-03 | 2024-02-15 | キュリス,インコーポレイテッド | Biomarkers for fimepinostat therapy |
WO2023275330A1 (en) * | 2021-06-30 | 2023-01-05 | Janssen Pharmaceutica Nv | Treatments for diffuse large b-cell lymphoma |
KR20240027767A (en) * | 2021-06-30 | 2024-03-04 | 얀센 파마슈티카 엔브이 | Inhibitors of Bruton's Tyrosine Kinase and Methods of Using the Same |
JP7423090B2 (en) * | 2022-04-07 | 2024-01-29 | 学校法人藤田学園 | B-cell lymphoma diagnostic aid kit and information provision method for patients with fever of unknown origin |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2575818A4 (en) * | 2010-06-03 | 2013-11-06 | Pharmacyclics Inc | The use of inhibitors of bruton's tyrosine kinase (btk) |
US20130102477A1 (en) * | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
EP2771010A4 (en) * | 2011-10-19 | 2015-04-01 | Pharmacyclics Inc | Use of inhibitors of bruton's tyrosine kinase (btk) |
WO2013063401A1 (en) * | 2011-10-28 | 2013-05-02 | Celgene Avilomics Research, Inc. | Methods of treating a bruton's tyrosine kinase disease or disorder |
KR20220093389A (en) * | 2012-06-04 | 2022-07-05 | 파마싸이클릭스 엘엘씨 | Crystalline forms of a bruton's tyrosine kinase inhibitor |
JP6575950B2 (en) * | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Mutations with resistance to Bruton tyrosine kinase (Btk) inhibitors |
CN105142639A (en) * | 2013-01-10 | 2015-12-09 | 林伯士艾瑞斯公司 | IRAK inhibitors and uses thereof |
-
2015
- 2015-07-31 CA CA2955744A patent/CA2955744A1/en not_active Abandoned
- 2015-07-31 MX MX2017001302A patent/MX2017001302A/en unknown
- 2015-07-31 BR BR112017001677-0A patent/BR112017001677A2/en not_active Application Discontinuation
- 2015-07-31 EP EP15828160.0A patent/EP3185870A4/en not_active Withdrawn
- 2015-07-31 SG SG11201700774UA patent/SG11201700774UA/en unknown
- 2015-07-31 RU RU2017106794A patent/RU2017106794A/en not_active Application Discontinuation
- 2015-07-31 CN CN201580049596.7A patent/CN106714804A/en active Pending
- 2015-07-31 US US14/815,921 patent/US20160032404A1/en not_active Abandoned
- 2015-07-31 JP JP2017504752A patent/JP2017523188A/en active Pending
- 2015-07-31 KR KR1020177005365A patent/KR20170042614A/en unknown
- 2015-07-31 AU AU2015296010A patent/AU2015296010A1/en not_active Abandoned
- 2015-07-31 WO PCT/US2015/043300 patent/WO2016019341A1/en active Application Filing
-
2017
- 2017-01-22 IL IL250221A patent/IL250221A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN106714804A (en) | 2017-05-24 |
JP2017523188A (en) | 2017-08-17 |
WO2016019341A1 (en) | 2016-02-04 |
IL250221A0 (en) | 2017-03-30 |
MX2017001302A (en) | 2017-10-11 |
RU2017106794A3 (en) | 2019-02-27 |
AU2015296010A1 (en) | 2017-02-02 |
US20160032404A1 (en) | 2016-02-04 |
EP3185870A1 (en) | 2017-07-05 |
CA2955744A1 (en) | 2016-02-04 |
RU2017106794A (en) | 2018-09-03 |
EP3185870A4 (en) | 2018-06-20 |
BR112017001677A2 (en) | 2018-07-17 |
KR20170042614A (en) | 2017-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250221A0 (en) | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor | |
IL272130B (en) | Inhibitors of lysine specific demethylase-1 | |
HK1224202A1 (en) | Primary carboxamides as btk inhibitors bik | |
CL2016002736A1 (en) | Lysine specific demethylase-1 inhibitors | |
IL250876B (en) | Inhibitors of lysine specific demethylase-1 | |
IL249733B (en) | Inhibitors of lysine specific demethylase-1 | |
EP2948458A4 (en) | Btk inhibitors | |
EP2948431A4 (en) | Btk inhibitors | |
IL249876A0 (en) | Inhibitors of lysine specific demethylase-1 | |
EP3140427A4 (en) | Biomarkers for response to pi3k inhibitors | |
DK3186242T3 (en) | ALFA-AMINO-BETA-CARBOXYMUCONSIDE-SEMIALDEHYDE-DECARBOXYLASE INHIBITORS | |
ZA201608555B (en) | Biomarkers for response to ezh2 inhibitors | |
HK1231556A1 (en) | Predictive method for determining tissual radiosensitivity | |
EP3176269A4 (en) | Novel biomarker for predicting sensitivity to met inhibitor, and use thereof | |
SG10201800570RA (en) | Biomarkers for assessing hiv | |
PT3126528T (en) | Methods for determining responsiveness to mek/erk inhibitors | |
FR3018717B1 (en) | MODEL FOR PREDICTING SURFACE RELEASE | |
IL252751A0 (en) | Assays for btk inhibitors | |
GB201416375D0 (en) | Analysis of cells on a substrate | |
GB201403199D0 (en) | A method of identifying candidate compounds | |
TH1601002924A (en) | New DGAT2 inhibitors | |
GB201421518D0 (en) | Touch operation of a touch device | |
UA30271S (en) | SET OF CASH FOR SHOES | |
TH1501006052A (en) | BACEI inhibitors |